Compare BridgeBio Pharma Inc (BBIO) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Verizon Communications Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Verizon Communications Inc trades at $47.26 (market cap $195.40B). The key difference: Verizon Communications Inc is far larger — about 11.8× BridgeBio Pharma Inc's market cap, and Verizon Communications Inc pays a 6.02% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | VZ | |
|---|---|---|
Market Cap | $16.61B | $195.40B |
Sector | Health | Media |
52-Week High | $90.17 | $51.38 |
52-Week Low | $47.29 | $38.40 |
Enterprise Value | $18.16B | $382.11B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Verizon (VZ) trades at $47.06, up 0.15% on the day, with a bullish technical signal and strong fundamentals including a P/E of 12.26 and a 6%+ dividend yield. Recent quarterly earnings have consistently beaten estimates, and cash flow from operations remains robust at $37.14 billion for 2025. The company is shifting focus to broadband growth and AI infrastructure, highlighted by a major dark fiber deal with Alphabet.
Outlook is positive with a consensus price target of $49.69, though competitive threats from SpaceX's Starlink and high debt levels pose risks. The stock offers value and income appeal, supported by analyst buy ratings and institutional accumulation, but investors must weigh growth initiatives against sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
